Urovant Sciences (UROV) Misses Q4 EPS by 44c

Urovant Sciences (NASDAQ: UROV) reported Q4 EPS of ($1.68), $0.44 worse than the analyst estimate of ($1.24).

“The 2019 fiscal year and fourth quarter have been transformational for our company,” said James Robinson, president and chief executive officer of Urovant Sciences. “With publication of data from the EMPOWUR study demonstrating that vibegron achieved statistical significance over placebo on both primary and all seven secondary endpoints, and FDA acceptance of our NDA, we look forward bringing to market a potentially best-in-class therapeutic option for the treatment of overactive bladder. Vibegron, if approved, could make a real difference in the lives of patients where there hasn’t been a new branded oral therapy launched in nearly a decade and where patient dissatisfaction and unmet need remains high.”

For earnings history and earnings-related data on Urovant Sciences (UROV) click here.

You May Also Be Interested In

• Virtuix delays Q1 FY2027 earnings report amid accounting firm switch
• Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c
• EquipmentShare.com Inc. (EQPT) Reports Q2 EPS of $0.18; Offers Guidance